A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus.

Trial Profile

A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Exenatide (Primary) ; Glucagon-like peptide-1
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2012 Actual patient number is 20 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual end date (15 Jun 2008) added as reported by EudraCT.
    • 15 Mar 2012 Planned number of patients changed from 20 to 28 as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top